BioWorld Asia

April 30, 2003

Diatos Licenses European Rights To Cancer Drug From Medarex

PARIS - Diatos SA and Medarex Inc. signed a licensing agreement giving Diatos exclusive European rights to develop and commercialize a potential new cancer treatment. (BioWorld International) Read More

Biotech Groups In Norway Unite, Plan To Catch Up With Neighbors

Genetic Study Of Clotting Enzyme Points To 'Fantastic' Drug Target

Curnock Cook Investing Again After Forming New €150M Fund

No Abstract Read More

PPL Gives Up Plans On Plant To Manufacture AAT Product

French Companies, Agency Unite For Effort In America

Alizyme Eyes Phase III, Alliance Following Renzapride Results

GenoWay Raises EUR3.3M To Fund Work On Animal, In Vitro Models

Merck Stops Development Of Celltech PDE-4 Inhibitor

UK Industry Gathers To Celebrate 50th Anniversary Of DNA Finding

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 30, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026